Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Citation data:

Journal of bone oncology, ISSN: 2212-1366, Vol: 7, Page: 1-12

Publication Year:
Usage 89
Abstract Views 84
Link-outs 3
Downloads 2
Captures 87
Readers 87
Mentions 5
News Mentions 5
Social Media 67
Shares, Likes & Comments 40
Tweets 27
Citations 23
Citation Indexes 23
Repository URL:
Hadji, Peyman; Aapro, Matti S; Body, Jean-Jacques; Gnant, Michael; Brandi, Maria Luisa; Reginster, Jean Yves; Zillikens, M Carola; Glüer, Claus-C; de Villiers, Tobie; Baber, Rod; Roodman, G David; Cooper, Cyrus; Langdahl, Bente; Palacios, Santiago; Kanis, John; Al-Daghri, Nasser; Nogues, Xavier; Eriksen, Erik Fink; Kurth, Andreas; Rizzoli, Rene; Coleman, Robert E Show More Hide
Elsevier BV
Medicine; Oncology
Most Recent Tweet View All Tweets
Most Recent News Mention
review description
Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL).